Company / Operating Cash Flow
Intellia Therapeutics, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$394.7M
FY2025
5-year range
-$394.7M / -$225.0M
FY2021-FY2025
Trend
-13.1%
vs FY2024
Sector context
#157 of 158
Health Care
What the data says
Among 158 Health Care companies, Intellia Therapeutics, Inc. is in the bottom 1% for operating cash flow. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$395M in FY2025 to $36M in FY2016.
Based on SEC 10-K filings.
-$395M in FY2025.
Remained stable around -$395M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 158This company -$394.7M Sector average $1.0B
▼
-138.2% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 13.1% year-over-year.
- Ranks #157 out of 158 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$394.7M | -13.1% |
| FY2024 | -$348.9M | +11.5% |
| FY2023 | -$394.1M | -18.2% |
| FY2022 | -$333.3M | -48.1% |
| FY2021 | -$225.0M | -350.9% |
| FY2020 | -$49.9M | +51.7% |
| FY2019 | -$103.2M | -68.5% |
| FY2018 | -$61.3M | +6.2% |
| FY2017 | -$65.3M | -280.8% |
| FY2016 | $36.1M | +2148.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026